Hepion Pharmaceuticals Successfully Completes Application to the OTCQB

Rhea-AI Summary

Hepion Pharmaceuticals (OTCQB:HEPA), a clinical stage biopharmaceutical company, has announced its successful transition to the OTCQB Venture Market. The company's common stock commenced trading on the OTCQB on June 25, 2025, under the symbol HEPA.

Hepion focuses on developing and commercializing diagnostic tests for multiple conditions including celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori, and hepatocellular carcinoma (HCC).

Positive

• None.

Negative

• Downgrade from previous listing to OTCQB market indicates potential delisting concerns
• Trading on OTCQB typically means reduced liquidity and institutional investor access compared to major exchanges

MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC), today announced that it has successfully completed the process of transitioning to the OTCQB Venture Market. The Company’s common stock begins trading on the OTCQB Venture Market today, June 25, 2025 with the trading symbol, HEPA.

About Hepion Pharmaceuticals

Hepion is a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma.

For further information, please contact:

Hepion Pharmaceuticals
info@hepionpharma.com

FAQ

What does Hepion Pharmaceuticals' (HEPA) move to OTCQB mean for investors?

The move to OTCQB indicates a downgrade in listing status, which typically means reduced liquidity and potentially limited access to institutional investors compared to major exchanges.

What diagnostic tests is Hepion Pharmaceuticals (HEPA) developing?

Hepion is developing diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC).

When did Hepion Pharmaceuticals (HEPA) begin trading on the OTCQB?

Hepion Pharmaceuticals began trading on the OTCQB Venture Market on June 25, 2025.

What is Hepion Pharmaceuticals' new trading symbol on the OTCQB?

Hepion Pharmaceuticals continues to trade under the symbol HEPA on the OTCQB.